Sugi Predict

Sugi Predict / Compounds / SCHEMBL715052

SCHEMBL715052

SCHEMBL715052

O=C(Nc1ccn(Cc2c(F)cccc2C(F)(F)F)n1)c1c(F)cccc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STIM1 Q13586 2/20 1.00
▸ ORAI1 Q96D31 2/20 1.00
▸ ORAI3 Q9BRQ5 1/20 0.69
▸ EGFR P00533 1/20 0.52
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ NPC1 O15118 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPT P10636 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ LMNA P02545 5/20 0.42
▸ NPSR1 Q6W5P4 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KLKB1 P03952 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096538 1.00 STIM1 (1.00) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL756322 0.92 STIM1 (0.86) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL758374 0.91 STIM1 (0.84) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL696244 0.89 STIM1 (0.80) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL759169 0.89 STIM1 (0.80) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL759947 0.89 STIM1 (0.79) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL760683 0.88 STIM1 (0.78) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL757813 0.85 STIM1 (0.74) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL755899 0.85 STIM1 (0.74) STIM1ORAI1ORAI3EGFRSMN1; SMN2
SCHEMBL760601 0.84 STIM1 (0.72) STIM1ORAI1ORAI3EGFRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230414609-A1 USES OF ORAI1-SPECIFIC CALCIUM CHANNELS IN TREATMENT OF ORAL CANCER NEW YORK UNIVERSITY 2023-12-28 — — US claimed
WO-2015187827-A1 NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-12-10 — — WO claimed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US claimed
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome CALCIMEDICA, INC. (US) 2026-02-10 — — US disclosed
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS AVENUE CAPITAL MANAGEMENT II, L.P. 2025-04-17 — — US disclosed
EP-4465988-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS Calcimedica, Inc. (US) 2024-11-27 — — EP disclosed
CN-118871110-A Methods and compositions for treating inflammatory lesions of the lung 钙医学公司 2024-10-29 — — CN disclosed
US-20230414609-A1 USES OF ORAI1-SPECIFIC CALCIUM CHANNELS IN TREATMENT OF ORAL CANCER NEW YORK UNIVERSITY 2023-12-28 — — US disclosed
WO-2023141523-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS CALCIMEDICA, INC. (US) 2023-07-27 — — WO disclosed
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME AVENUE CAPITAL MANAGEMENT II, L.P. 2023-04-20 — — US disclosed
CN-115835878-A Methods and compositions for treating acute lung injury and acute respiratory distress syndrome 钙医学公司 2023-03-21 — — CN disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
EP-2421835-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS Glaxo Group Limited (GB) 2012-02-29 — — EP disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome ORAI1, MAVS, CASR STIM1 231/4885ORAI1 1/4885ORAI3 632/4885
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS ORAI1, TRPV1, CACNA1E STIM1 33/4885ORAI1 1/4885ORAI3 25/4885
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS IL1B, MAVS, MMP8 STIM1 852/4885ORAI1 92/4885ORAI3 1278/4885
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME MAVS, ATF1, IL1B STIM1 943/4885ORAI1 68/4885ORAI3 1408/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 STIM1 2564/4885ORAI1 3127/4885ORAI3 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.